亚洲欧美不卡高清在线观看,伊人久久大香线蕉午夜av,亚洲综合色区在线观看,中文在线中文a,真正免费的毛片

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Suven Life Sciences granted patent for neuro-degenerative drug

expressbpdAugust 18, 2017

Tag: Suven Life Sciences , New Chemical Entities (NCEs) , neuro-degenerative drug

Suven Life Sciences has been granted a patent each by Europe, Japan and New Zealand for a drug used in the treatment of neuro-degenerative diseases.

The patents are valid till 2034, the company added.

The company said in a BSE filing said that it has been granted "one process patent from Europe, one process patent from Japan and one process patent from New Zealand corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with neurodegenerative diseases."

The patents are valid till 2034, the company added.

"We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Venkat Jasti, CEO, Suven Life.

Previous:Abbott’s nutrition metabolic formulas to help infants diagnosed with IEM

Next:Piramal arm DRG acquires US firm Context Matters

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service